NASDAQ Companies

– Accepted with Prescription Drug User Fee Act (PDUFA) action date of November 29, 2024; FDA not currently planning to […]

— Preliminary data includes 26 and 52-week follow-up end points as part of ongoing Phase 2 trial — — Company […]

ROGERS, Ark., Feb. 05, 2024 (GLOBE NEWSWIRE) — America’s Car-Mart, Inc. (NASDAQ: CRMT) today announced it will release fiscal 2024 […]

Lawsuit alleges false and misleading advertising and promotion of unapproved cantharidin-containing drugs by Dormer Laboratories in violation of federal and […]

Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional […]

NEW YORK, Feb. 05, 2024 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated […]

– Presentation to be Webcast and Archived – BRIDGEVILLE, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) — Universal Stainless & Alloy […]

SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced it will host Part I of […]

RESEARCH TRIANGLE PARK, N.C. , Feb. 05, 2024 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company […]

LONDON and RESTON, Va., Feb. 05, 2024 (GLOBE NEWSWIRE) — Arqit Quantum Inc. (Nasdaq: ARQQ, ARQQW) (Arqit), a leader in […]